NAD+ Decline, NNMT, and the Peptide Approach to Cellular Energy: Why Precursors Alone Aren’t Enough

Introduction: The NAD+ Crisis in Aging

By the time you reach 60, your cellular NAD+ levels have dropped to roughly half of what they were at 20. This isn’t a minor biochemical curiosity — it’s a metabolic catastrophe that cascades through virtually every system in the body. NAD+ (nicotinamide adenine dinucleotide) isn’t just another molecule; it’s arguably the most important coenzyme in human biology, participating in over 500 enzymatic reactions that govern everything from DNA repair to mitochondrial energy production to circadian rhythm regulation.

The supplement industry has responded to this crisis with a massive push toward NAD+ precursor supplementation — primarily NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Global sales of NAD+ precursors exceeded $500 million in 2025, driven by compelling preclinical research and aggressive consumer marketing. But a growing body of evidence suggests that simply flooding the system with precursors may be insufficient — and the reason comes down to an enzyme most consumers have never heard of: NNMT (nicotinamide N-methyltransferase).

This comprehensive guide explores the science behind NAD+ decline, why precursor-only strategies have fundamental limitations, and how emerging peptide-based approaches — particularly NNMT inhibition — may offer a more complete solution to the NAD+ crisis. We examine the latest research from 2025-2026, dissect the molecular mechanisms, and explore the combination strategies that researchers believe could fundamentally change how we approach cellular energy and aging.

What Is NAD+ and Why Does It Matter?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It exists in two forms: the oxidized form (NAD+) and the reduced form (NADH), and the ratio between these forms is a critical determinant of cellular metabolic state.

The Four Essential Roles of NAD+

1. Metabolic Electron Transfer: NAD+ is an essential cofactor in glycolysis, the TCA (Krebs) cycle, and oxidative phosphorylation — the three major pathways of cellular energy production. It accepts electrons from metabolic intermediates (becoming NADH) and donates them to the electron transport chain to drive ATP synthesis. Without sufficient NAD+, cellular energy production grinds to a halt.

2. Sirtuin Activation: NAD+ is the obligate co-substrate for the sirtuin family of enzymes (SIRT1-7), which function as NAD+-dependent protein deacetylases and ADP-ribosyltransferases. Sirtuins regulate gene expression, stress responses, metabolism, and aging processes. When NAD+ drops, sirtuin activity drops proportionally — silencing the very enzymes that protect against age-related decline.

3. DNA Repair (PARP Enzymes): Poly(ADP-ribose) polymerases (PARPs), particularly PARP1, consume NAD+ to catalyze DNA repair. As DNA damage accumulates with age and environmental exposure, PARP activity increases, consuming more NAD+ and creating a vicious cycle: more damage ? more PARP activity ? less NAD+ ? impaired sirtuin function ? more damage.

4. Immune Cell Signaling (CD38): CD38 is an NAD+-consuming enzyme expressed on immune cells that increases dramatically with age and inflammation. CD38-mediated NAD+ consumption is now recognized as one of the primary drivers of age-related NAD+ decline — a critical piece of the puzzle that precursor supplementation alone cannot adequately address.

The Science of NAD+ Decline: What Happens as We Age

The age-related decline in NAD+ is not a single event but a convergence of multiple mechanisms that collectively overwhelm the cell’s ability to maintain NAD+ homeostasis:

Increased Consumption

As organisms age, the demand for NAD+ increases. DNA damage accumulates, requiring more PARP activity. Chronic low-grade inflammation (“inflammaging”) drives increased CD38 expression. Metabolic stress increases sirtuin demand. The result is a steadily growing NAD+ consumption rate that outpaces production.

Decreased Production

Simultaneously, NAD+ biosynthesis becomes less efficient with age. The expression and activity of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway, decreases in multiple tissues with aging. Additionally, increased NNMT expression in adipose tissue and liver diverts nicotinamide — the primary salvage pathway substrate — toward wasteful methylation rather than NAD+ recycling.

The Salvage Pathway Bottleneck

The NAD+ salvage pathway recycles nicotinamide (produced when sirtuins, PARPs, and CD38 consume NAD+) back into NAD+. This pathway — nicotinamide ? NMN (via NAMPT) ? NAD+ (via NMNAT) — handles approximately 85% of NAD+ production in most tissues. When both NAMPT activity decreases and NNMT diverts nicotinamide away from NAMPT, the salvage pathway’s throughput drops at both the supply (less nicotinamide entering) and enzymatic (lower NAMPT activity) levels.

“NAD+ decline is not simply a matter of reduced production — it is the convergence of increased consumption, decreased synthesis, and active diversion of precursors. Addressing only one of these factors leaves the other two unopposed.” — Adapted from Chini et al., Nature Reviews Endocrinology, 2024

NMN and NR: Why Precursors Alone Fall Short

The precursor supplementation strategy is intuitively appealing: if NAD+ levels are low, provide more building blocks. NMN (nicotinamide mononucleotide) enters the salvage pathway one step before NAD+ synthesis, while NR (nicotinamide riboside) enters two steps before. Both have demonstrated the ability to raise tissue NAD+ levels in preclinical studies and, to varying degrees, in human trials.

However, several limitations have become increasingly apparent:

1. The NNMT Diversion Problem

NMN and NR are ultimately metabolized through pathways that produce nicotinamide as a byproduct. When cells use NAD+ (via sirtuins, PARPs, or CD38), nicotinamide is released and must be recycled. But if NNMT activity is elevated — as it is in obesity, aging, and metabolic disease — a significant fraction of this nicotinamide is methylated to 1-methylnicotinamide (1-MNA) and excreted, rather than being recycled back to NAD+. This creates a “leaky bucket” scenario: you’re pouring in more precursor, but the bucket has a hole.

2. Dose-Response Ceiling Effects

Human clinical trials with NMN and NR have shown inconsistent dose-response relationships. Some studies show robust NAD+ increases at moderate doses but diminishing returns at higher doses, suggesting saturation of biosynthetic enzymes or increased clearance at higher precursor loads. A 2023 meta-analysis found that while NR consistently raised blood NAD+ levels by 40-90% in healthy volunteers, the translation to functional endpoints (mitochondrial function, insulin sensitivity, exercise capacity) was inconsistent (PMID: 36445729).

3. Tissue-Specific Limitations

Not all tissues respond equally to oral precursor supplementation. NMN has demonstrated good bioavailability in some tissues (liver, muscle) but limited penetration to others (brain, adipose tissue). NR similarly shows variable tissue distribution. The tissues most affected by NAD+ decline (brain, heart, skeletal muscle in the elderly) may not receive sufficient precursor to meaningfully restore NAD+ levels.

4. The CD38 Problem

Even if precursor supplementation successfully raises NAD+ levels, elevated CD38 activity in aging tissues will rapidly consume the additional NAD+. CD38 is a remarkably inefficient enzyme — it consumes approximately 100 molecules of NAD+ for every molecule of cyclic ADP-ribose (its signaling product) it produces. In aged mice, CD38 expression increases 2-3 fold, and CD38 knockout mice maintain youthful NAD+ levels into old age (PMID: 27304511).

5. Potential Safety Signals

A controversial 2024 study raised concerns about potential oncogenic effects of chronic NMN supplementation at high doses in certain cancer-prone mouse models, though the findings remain debated and have not been replicated. Additionally, the methylation burden of high-dose nicotinamide-based precursors (particularly through increased NNMT activity) could theoretically deplete SAM pools, affecting global methylation capacity. These concerns remain theoretical but underscore the need for more nuanced approaches than simple precursor flooding.

The NNMT Problem: Your Body’s NAD+ Drain

NNMT (nicotinamide N-methyltransferase) has emerged as one of the most important yet least understood regulators of NAD+ homeostasis. This enzyme catalyzes a deceptively simple reaction: it transfers a methyl group from SAM (S-adenosyl-L-methionine) to nicotinamide, producing 1-methylnicotinamide (1-MNA) and SAH (S-adenosyl-L-homocysteine).

The consequences of this reaction are far-reaching:

Nicotinamide Diversion

Every molecule of nicotinamide methylated by NNMT is one molecule that cannot enter the NAD+ salvage pathway. In tissues with high NNMT expression (liver, adipose tissue, kidney), a substantial fraction of the available nicotinamide pool is diverted toward 1-MNA production. This is particularly problematic because nicotinamide is the predominant NAD+ precursor in most tissues — it’s both the starting substrate and the recycling intermediate of the salvage pathway.

Age and Obesity Upregulation

NNMT expression increases with age and is dramatically elevated in the adipose tissue of obese individuals. The landmark Kraus et al. (2014) Nature study showed that NNMT expression in human white adipose tissue correlated positively with BMI, insulin resistance, and adipocyte size. This creates a particularly cruel metabolic double bind: the people who most need adequate NAD+ levels (the obese and elderly) are the ones whose NNMT is most active in draining it (PMID: 24670636).

A Target for Intervention

This is precisely why NNMT inhibition has generated such excitement in the longevity and metabolic research communities. If NNMT is actively draining the nicotinamide pool, then inhibiting NNMT should redirect that nicotinamide back toward NAD+ synthesis — effectively “plugging the drain” rather than just “filling the bucket faster.” The most well-characterized pharmacological tool for NNMT inhibition is 5-Amino-1MQ, a small-molecule competitive inhibitor.

The Methylation Drain: How NNMT Steals From Two Systems

NNMT’s metabolic cost extends beyond NAD+ depletion. Because the enzyme uses SAM as its methyl donor, high NNMT activity simultaneously drains two critical metabolic systems:

System 1: NAD+ Metabolism

As described above, nicotinamide diversion reduces NAD+ salvage pathway flux, leading to lower intracellular NAD+ levels and reduced sirtuin/PARP activity.

System 2: One-Carbon/Methylation Metabolism

SAM is the universal methyl donor in mammalian biochemistry. It provides methyl groups for DNA methylation (epigenetic regulation), histone methylation (gene expression control), phospholipid methylation (membrane biology), creatine synthesis, and hundreds of other methyltransferase reactions. When NNMT consumes SAM at high rates, it depletes the methylation pool and produces SAH, which is a potent product inhibitor of other methyltransferases.

The net effect is that high NNMT activity simultaneously:

• Reduces NAD+ availability (impairing energy production, DNA repair, and sirtuin signaling)
• Depletes SAM (impairing epigenetic regulation, gene expression control, and other methylation-dependent processes)
• Increases SAH (inhibiting other methyltransferases, further disrupting methylation homeostasis)

This “double drain” effect explains why NNMT inhibition produces such broadly beneficial metabolic effects in preclinical models — it simultaneously restores two of the cell’s most important metabolic currencies.

CD38: The Second Major NAD+ Drain

While NNMT drains NAD+ indirectly (by diverting precursors), CD38 drains it directly. CD38 is a transmembrane glycoprotein originally identified as a lymphocyte surface marker, but now recognized as the dominant NAD+-consuming enzyme in most mammalian tissues.

Key facts about CD38’s role in NAD+ decline:

• Expression increases 2-3 fold with aging in multiple tissues (liver, brain, adipose, spleen)
• CD38 is catalytically wasteful — it hydrolyzes ~100 NAD+ molecules for every cyclic ADP-ribose molecule it produces
• CD38 knockout mice maintain youthful NAD+ levels into old age and show protection against age-related metabolic decline
• Senescent cells and activated macrophages express particularly high levels of CD38, linking NAD+ decline to cellular senescence and inflammation
• The flavonoid apigenin has been identified as a natural CD38 inhibitor, and synthetic CD38 inhibitors are in preclinical development

The CD38 and NNMT pathways represent two independent “drains” on the NAD+ pool, operating through completely different mechanisms. This has important implications for intervention strategy: optimal NAD+ restoration may require addressing both drains simultaneously, rather than relying on precursor supplementation alone.

Sirtuins, FOXO, and the NAD+-Longevity Axis

The connection between NAD+, sirtuins, and longevity represents one of the most well-characterized pathways in aging research. The seven mammalian sirtuins (SIRT1-7) function as NAD+-dependent deacetylases and ADP-ribosyltransferases, removing acetyl groups from histone and non-histone proteins to regulate gene expression, metabolism, and stress responses.

SIRT1: The Metabolic Master Switch

SIRT1, the most studied sirtuin, deacetylates key transcription factors including:

• FOXO1/3: Activating antioxidant gene expression, autophagy, and stress resistance
• PGC-1?: Promoting mitochondrial biogenesis, fatty acid oxidation, and oxidative metabolism
• NF-?B: Suppressing inflammatory gene transcription
• p53: Modulating DNA damage response and apoptosis
• SREBP: Regulating lipid and cholesterol metabolism

When NAD+ levels drop, SIRT1 activity decreases proportionally, leading to hyperacetylation of these targets, reduced mitochondrial function, increased inflammation, and impaired stress responses — a constellation of changes that closely mirrors the aging phenotype.

SIRT3: The Mitochondrial Guardian

SIRT3 resides in the mitochondrial matrix and deacetylates key enzymes in fatty acid oxidation, the TCA cycle, and the electron transport chain. NAD+-dependent SIRT3 activity is essential for maintaining mitochondrial protein homeostasis and preventing the accumulation of hyperacetylated, dysfunctional mitochondrial enzymes that characterize aged tissues.

The FOXO Connection

FOXO (Forkhead box O) transcription factors are major sirtuin targets with direct relevance to longevity. SIRT1-mediated deacetylation of FOXO proteins activates transcriptional programs for:

• Superoxide dismutase and catalase (antioxidant defense)
• Autophagy genes (cellular cleanup)
• DNA repair enzymes
• Cell cycle arrest genes (cancer protection)
• Gluconeogenic enzymes (metabolic flexibility)

The NAD+ ? SIRT1 ? FOXO axis is considered one of the most conserved longevity pathways across species, from yeast to mammals. Restoring NAD+ levels in aged organisms reactivates this axis, producing many of the protective effects associated with caloric restriction — without the caloric restriction.

Mitochondrial Function and the NAD+/NADH Ratio

Mitochondrial dysfunction is a hallmark of aging, and the NAD+/NADH ratio is a critical determinant of mitochondrial health. This ratio reflects the cell’s overall metabolic and redox state:

• High NAD+/NADH ratio: Indicates active oxidative metabolism, efficient electron transport chain function, and adequate energy production capacity
• Low NAD+/NADH ratio: Indicates impaired oxidative metabolism, electron transport chain congestion, increased reactive oxygen species (ROS) production, and a shift toward reductive stress

As NAD+ declines with age, the NAD+/NADH ratio decreases, creating a state of “pseudohypoxia” where mitochondria behave as if oxygen is limited even when it isn’t. This pseudohypoxic state has been directly linked to multiple age-related pathologies and can be reversed by restoring NAD+ levels.

Mitochondria-derived peptides represent a fascinating endogenous response to mitochondrial stress that may complement exogenous NAD+ restoration strategies. These peptides, encoded in the mitochondrial genome, are expressed in response to mitochondrial dysfunction and appear to have systemic protective effects.

Peptide-Based Approaches to NAD+ Restoration

While NAD+ precursor supplements address the supply side of NAD+ metabolism, peptide-based approaches offer mechanisms that target different aspects of the NAD+ crisis — from blocking enzymatic drains to enhancing mitochondrial function to mimicking the downstream effects of adequate NAD+ levels.

5-Amino-1MQ: Blocking the NNMT Drain

5-Amino-1MQ is a small-molecule competitive inhibitor of NNMT that has demonstrated potent effects on fat metabolism and NAD+ homeostasis in preclinical studies. Its mechanism is elegantly simple: by occupying the NNMT active site, it prevents the enzyme from methylating nicotinamide, thereby redirecting nicotinamide back into the NAD+ salvage pathway.

The key findings relevant to NAD+ biology:

• Increased intracellular NAD+: By blocking NNMT-mediated nicotinamide diversion, 5-Amino-1MQ increases the pool of nicotinamide available for NAD+ synthesis through the salvage pathway
• Preserved SAM levels: By reducing NNMT’s consumption of SAM, the compound also preserves the cell’s methylation capacity
• Enhanced sirtuin activity: Increased NAD+ availability should theoretically enhance sirtuin-mediated deacetylation of metabolic targets (FOXO, PGC-1?, SREBP)
• Fat-specific metabolic effects: In diet-induced obese mice, 5-Amino-1MQ reduced body weight, fat mass, and cholesterol without affecting food intake or lean mass — effects consistent with enhanced NAD+-dependent metabolic programs in adipose tissue (PMID: 28525751)

The compound’s particular value in the NAD+ context is that it addresses a root cause of NAD+ decline — precursor diversion — rather than simply adding more precursor to an already leaky system.

MOTS-c: The Mitochondrial-Derived Exercise Mimetic

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded in the mitochondrial genome. Discovered by Changhan David Lee’s laboratory at USC in 2015, MOTS-c has emerged as a key regulator of cellular metabolism with direct relevance to NAD+ biology (PMID: 25738459).

How MOTS-c Connects to NAD+ Metabolism

• AMPK activation: MOTS-c activates AMP-activated protein kinase (AMPK), the cell’s master energy sensor. AMPK activation promotes NAD+ biosynthesis by upregulating NAMPT expression, directly increasing the salvage pathway’s capacity to produce NAD+
• Mitochondrial biogenesis: Through AMPK and downstream activation of PGC-1?, MOTS-c promotes the generation of new mitochondria, increasing the cell’s total oxidative capacity and NAD+/NADH cycling efficiency
• Exercise-mimetic effects: MOTS-c reproduces many of the metabolic benefits of exercise — improved insulin sensitivity, enhanced glucose uptake, increased fatty acid oxidation — that are mechanistically linked to NAD+-dependent pathways
• Age-related decline: Circulating MOTS-c levels decrease with age, paralleling the decline in NAD+ and mitochondrial function. Exogenous MOTS-c administration in aged mice restored metabolic parameters toward youthful levels

MOTS-c represents a fundamentally different approach to the NAD+ problem — rather than directly modulating NAD+ levels, it enhances the cellular systems that depend on NAD+ and promotes endogenous NAD+ production through AMPK-NAMPT signaling.

For researchers interested in exercise mimetic peptides, SLU-PP-332 (an ERR? agonist) represents another approach to activating exercise-associated metabolic programs through a complementary mechanism.

Humanin and Other Mitochondrial Peptides

MOTS-c is part of a larger family of mitochondrial-derived peptides (MDPs) that serve as retrograde signals from mitochondria to the nucleus and systemic circulation:

Humanin

A 24-amino acid peptide encoded in the mitochondrial 16S rRNA gene, humanin was discovered in 2001 in a screen for factors protecting against Alzheimer’s disease-related cell death. It has demonstrated cytoprotective, neuroprotective, and metabolic protective effects in multiple model systems. Humanin levels also decline with age, and its administration improves insulin sensitivity and reduces oxidative stress in aged rodents.

SHLP1-6 (Small Humanin-Like Peptides)

Six additional peptides encoded in the same mitochondrial 16S rRNA region show diverse biological activities including insulin sensitization, anti-inflammatory effects, and cellular stress protection. These peptides represent a mitochondrial “signaling system” that communicates mitochondrial health status to the rest of the cell and body.

The MDP-NAD+ Connection

The common thread linking these mitochondrial peptides to NAD+ biology is that they are expressed in response to mitochondrial stress — the same stress that characterizes NAD+ depletion. They function as adaptive signals that activate compensatory programs (AMPK, UPRmt, FOXO, antioxidant defense) designed to restore mitochondrial function. In this framework, exogenous MDP administration supplements a naturally declining endogenous signal, potentially restoring the cellular stress response capacity that erodes with NAD+ decline.

Combination Strategies: Precursors + Drain Blockers + Peptides

The most sophisticated approach to NAD+ restoration involves simultaneously addressing multiple mechanisms of decline. Researchers are increasingly exploring combination strategies that target both supply and demand sides of NAD+ metabolism:

Strategy 1: Precursor + NNMT Inhibitor

Rationale: Supply more nicotinamide/NMN/NR (precursor) while blocking its diversion by NNMT (drain blocker). This “fill the bucket + plug the drain” approach addresses both sides of the salvage pathway bottleneck.

Predicted outcome: Greater and more sustained NAD+ elevation than either approach alone, with improved tissue penetration as more precursor reaches the salvage pathway enzymes rather than being diverted to 1-MNA.

Example: NMN supplementation + 5-Amino-1MQ

Strategy 2: NNMT Inhibitor + CD38 Inhibitor

Rationale: Block both major NAD+ drains simultaneously — NNMT (precursor diversion) and CD38 (direct NAD+ consumption). This dual-drain-blocker approach could dramatically reduce the total rate of NAD+ loss.

Predicted outcome: Maximal preservation of endogenous NAD+, potentially reducing or eliminating the need for high-dose precursor supplementation.

Example: 5-Amino-1MQ + apigenin (natural CD38 inhibitor)

Strategy 3: Precursor + NNMT Inhibitor + Mitochondrial Peptide

Rationale: The comprehensive approach — increase NAD+ supply (precursor), reduce NAD+ waste (NNMT inhibitor), and enhance the mitochondrial function that depends on NAD+ (MOTS-c). This three-pronged strategy addresses supply, conservation, and utilization.

Predicted outcome: Not just higher NAD+ levels, but more efficient NAD+ utilization and enhanced downstream signaling through AMPK, sirtuins, and mitochondrial pathways.

Example: NMN + 5-Amino-1MQ + MOTS-c

Strategy 4: NAD+ Restoration + Exercise Mimetics

Rationale: Exercise is the most potent natural activator of AMPK, NAMPT, and sirtuin pathways. Exercise mimetics like SLU-PP-332 (ERR? agonist) or MOTS-c (AMPK activator) could amplify the benefits of NAD+ restoration by ensuring the downstream pathways are fully activated.

Example: NMN + 5-Amino-1MQ + SLU-PP-332

It’s important to emphasize that these combination strategies are theoretical and require rigorous experimental validation. The interactions between these pathways are complex, and combination effects cannot be reliably predicted from individual component studies alone.

Latest Research Developments (2025-2026)

The field of NAD+ research continues to evolve rapidly. Key developments from 2025-2026 include:

NMN Human Trial Results

Several larger, longer-duration NMN clinical trials have reported results, providing a clearer picture of what precursor supplementation can and cannot achieve in humans. While NAD+ blood level increases are consistently demonstrated (40-90% elevation), the translation to functional endpoints remains mixed. Some studies show benefits in muscle function and insulin sensitivity in older adults, while others fail to demonstrate significant improvements over placebo in well-controlled designs.

CD38 as the Dominant NAD+ Consumer

Research from the Chini laboratory has further established CD38 as the single largest contributor to age-related NAD+ decline, with CD38-mediated consumption potentially accounting for 60-70% of total NAD+ loss in aged tissues. This finding has shifted attention toward CD38 inhibitor development and has raised questions about whether precursor supplementation can meaningfully restore NAD+ without simultaneously addressing CD38 activity (PMID: 33432230).

Tissue-Specific NAD+ Mapping

Advanced metabolomics techniques have enabled more precise mapping of NAD+ levels and salvage pathway activity across different tissues and cell types. This work has revealed striking tissue-specific differences in which NAD+ consumption pathway dominates (PARP-heavy in DNA damage-prone tissues, CD38-heavy in immune-infiltrated tissues, NNMT-heavy in metabolically active adipose and liver tissue), suggesting that optimal NAD+ restoration strategies may need to be tissue-targeted.

NNMT Inhibitor Development

Beyond 5-Amino-1MQ, next-generation NNMT inhibitors with improved potency, selectivity, and pharmacokinetic properties are in preclinical development. These include bisubstrate inhibitors that simultaneously occupy both the nicotinamide and SAM binding sites, offering potentially greater inhibitory potency and selectivity.

The Senescence-NAD+ Connection

Cellular senescence (the accumulation of permanently growth-arrested cells with age) has been linked to local NAD+ depletion through the senescence-associated secretory phenotype (SASP). Senescent cells upregulate CD38 expression in neighboring immune cells, creating local NAD+ “dead zones.” Senolytic compounds that clear senescent cells have been shown to restore local NAD+ levels, suggesting that senescence and NAD+ decline are mechanistically linked.

Frequently Asked Questions

References

1. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513-528. PMID: 29249689
2. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127-1139. PMID: 27304511
3. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. PMID: 24670636
4. Neelakantan H, Wang HY, Vance V, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. PMID: 28525751
5. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
6. Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. PMID: 24786309
7. Chini EN, Chini CCS, Espindola Netto JM, de Oliveira GC, van Schooten W. The pharmacology of CD38/NADase: an emerging target in cancer and diseases of aging. Trends Pharmacol Sci. 2018;39(4):424-436. PMID: 29458944
8. Gomes AP, Price NL, Ling AJY, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638. PMID: 24360282
9. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. PMID: 33432230
10. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. PMID: 29514064
11. Pirinen E, Auranen M, Khan NA, et al. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metab. 2020;31(6):1078-1090. PMID: 32386566
12. Hong S, Moreno-Navarrete JM, Wei X, et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med. 2015;21(8):887-894. PMID: 26168293
13. Yi L, Maier AB, Tao R, et al. The efficacy and safety of ?-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. PMID: 36445729
14. Hashimoto T, Horikawa M, Nomura T, Sakamoto K. Nicotinamide adenine dinucleotide extends the lifespan of Caenorhabditis elegans mediated by sir-2.1 and daf-16. Biogerontology. 2010;11(1):31-43. PMID: 19430956

About Proxiva Labs: We supply premium research-grade compounds for NAD+ and metabolic research, including 5-Amino-1MQ, MOTS-c, NAD+ Nasal Spray, and SLU-PP-332. All products undergo rigorous third-party purity testing. Browse our full research compound catalog.